ONCS.Q Stock Overview
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
OncoSec Medical Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.13 |
| 52 Week High | US$18.99 |
| 52 Week Low | US$0.11 |
| Beta | 2 |
| 11 Month Change | -68.98% |
| 3 Month Change | -94.83% |
| 1 Year Change | -99.25% |
| 33 Year Change | -99.70% |
| 5 Year Change | -99.95% |
| Change since IPO | -98.61% |
Recent News & Updates
Recent updates
OncoSec to cut workforce by 45% as part of corporate restructuring
Oct 04What Type Of Shareholders Make Up OncoSec Medical Incorporated's (NASDAQ:ONCS) Share Registry?
Jan 28
Dosing underway in OncoSec's Tavo combo trial in skin cancer
Jan 08OncoSec: Undervalued And Continuing To Make Progress
Nov 18OncoSec drops 11% despite positive data from TAVO + Merck's Keytruda in metastatic melanoma
Nov 09Shareholder Returns
| ONCS.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -36.5% | 2.4% | 0.5% |
| 1Y | -99.3% | 15.6% | 30.7% |
Return vs Industry: ONCS.Q underperformed the US Biotechs industry which returned -3.5% over the past year.
Return vs Market: ONCS.Q underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| ONCS.Q volatility | |
|---|---|
| ONCS.Q Average Weekly Movement | 28.4% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ONCS.Q's share price has been volatile over the past 3 months.
Volatility Over Time: ONCS.Q's weekly volatility (28%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 41 | n/a | oncosec.com |
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company’s product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma.
OncoSec Medical Incorporated Fundamentals Summary
| ONCS.Q fundamental statistics | |
|---|---|
| Market cap | US$804.96k |
| Earnings (TTM) | -US$29.39m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs ONCS.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONCS.Q income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$29.39m |
| Earnings | -US$29.39m |
Last Reported Earnings
Jan 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.93 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -132.9% |
How did ONCS.Q perform over the long term?
See historical performance and comparison